Publications by authors named "H Jourdain"
Background: Since 2020, trastuzumab deruxtecan (T-DXd) has been used in France for patients with previously treated human epidermal growth factor receptor 2 (HER2)-positive or HER2-low metastatic breast cancer (mBC). We aimed to describe the clinical characteristics, outcomes, and potential toxicities among patients receiving T-DXd for HER2-positive and HER2-low mBC.
Patients And Methods: Using the French National Health Data System (SNDS), we identified patients who initiated T-DXd for mBC from 30 September 2020 to 30 September 2023.
Background: The lack of evidence under routine clinical settings limited the widespread adoption of adalimumab biosimilars for psoriasis treatment.
Objective: This study compared the drug survival and safety of adalimumab biosimilars to Humira for psoriasis treatment.
Methods: We conducted a prevalent new-user cohort study using data from the French National Health Data System (SNDS), the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR), and the Spanish Registry of Systemic Therapy in Psoriasis (BIOBADADERM).
Melanoma is a malignant tumour with a poorer prognosis in stage III and IV patients. Development of effective therapies for the treatment of advanced melanoma has led to an improvement in survival. Furthermore, the French population is ageing, and treatment of melanoma in this population has several specific limitations.
View Article and Find Full Text PDFIntroduction: Trastuzumab deruxtecan (T-DXd) has been approved for human epidermal growth factor receptor 2-positive locally advanced or metastatic gastric and gastroesophageal junction (HER2+ mG/GEJ) cancer since July 2022 in France, through an accelerated approval. The aim of this study was to evaluate its real-world use.
Methods: We characterized T-DXd users treated for HER2+ mG/GEJ cancer using data from the French National Health Insurance database.
Article Synopsis
- The study aimed to compare the persistence and safety of biosimilar medications versus their originator counterparts for infliximab, etanercept, and adalimumab in various medical conditions.
- Researchers utilized extensive data from the French National Health Data System, tracking nearly 87,000 patients from the launch of biosimilars in 2015, 2016, and 2018 until June 2021, with a follow-up period of one year.
- Results indicated no significant difference in treatment discontinuation rates or safety events, suggesting biosimilars are as safe and effective as their originators across all licensed indications.